Harden TK - Search Results

1

A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils.

Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, Harden TK. Barrett MO, et al. Among authors: harden tk. Mol Pharmacol. 2013 Jul;84(1):41-9. doi: 10.1124/mol.113.085654. Epub 2013 Apr 16. Mol Pharmacol. 2013. PMID: 23592514 Free PMC article.

2

Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, Harden TK. Waldo GL, et al. Among authors: harden tk. Mol Pharmacol. 2002 Nov;62(5):1249-57. doi: 10.1124/mol.62.5.1249. Mol Pharmacol. 2002. PMID: 12391289 Free PMC article.

3

Release of cellular UDP-glucose as a potential extracellular signaling molecule.

Lazarowski ER, Shea DA, Boucher RC, Harden TK. Lazarowski ER, et al. Among authors: harden tk. Mol Pharmacol. 2003 May;63(5):1190-7. doi: 10.1124/mol.63.5.1190. Mol Pharmacol. 2003. PMID: 12695547

4

Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules.

Lazarowski ER, Boucher RC, Harden TK. Lazarowski ER, et al. Among authors: harden tk. Mol Pharmacol. 2003 Oct;64(4):785-95. doi: 10.1124/mol.64.4.785. Mol Pharmacol. 2003. PMID: 14500734 Review. No abstract available.

5

Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog.

Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK. Chhatriwala M, et al. Among authors: harden tk. J Pharmacol Exp Ther. 2004 Dec;311(3):1038-43. doi: 10.1124/jpet.104.068650. Epub 2004 Sep 2. J Pharmacol Exp Ther. 2004. PMID: 15345752 Free PMC article.

6

[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. Houston D, et al. Among authors: harden tk. Br J Pharmacol. 2006 Mar;147(5):459-67. doi: 10.1038/sj.bjp.0706453. Br J Pharmacol. 2006. PMID: 16299552 Free PMC article.

7

UDP is a competitive antagonist at the human P2Y14 receptor.

Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, Harden TK. Fricks IP, et al. Among authors: harden tk. J Pharmacol Exp Ther. 2008 May;325(2):588-94. doi: 10.1124/jpet.108.136309. Epub 2008 Feb 5. J Pharmacol Exp Ther. 2008. PMID: 18252808 Free PMC article.

8

Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor.

Houston D, Costanzi S, Jacobson KA, Harden TK. Houston D, et al. Among authors: harden tk. Comb Chem High Throughput Screen. 2008 Jul;11(6):410-9. doi: 10.2174/138620708784911474. Comb Chem High Throughput Screen. 2008. PMID: 18673269 Free PMC article. Review.

9

Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems.

Fricks IP, Carter RL, Lazarowski ER, Harden TK. Fricks IP, et al. Among authors: harden tk. J Pharmacol Exp Ther. 2009 Jul;330(1):162-8. doi: 10.1124/jpet.109.150730. Epub 2009 Apr 1. J Pharmacol Exp Ther. 2009. PMID: 19339661 Free PMC article.

10

Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor.

Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, Jacobson KA, Lazarowski ER, Harden TK. Carter RL, et al. Among authors: harden tk. Mol Pharmacol. 2009 Dec;76(6):1341-8. doi: 10.1124/mol.109.058578. Epub 2009 Sep 16. Mol Pharmacol. 2009. PMID: 19759354 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters